KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Short term Debt: 2024

Historic Short term Debt for Alnylam Pharmaceuticals (ALNY) over the last 1 years, with Dec 2024 value amounting to $93.8 million.

  • Alnylam Pharmaceuticals' Short term Debt was N/A to $121.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year change of. This contributed to the annual value of $93.8 million for FY2024, which is N/A change from last year.
  • Alnylam Pharmaceuticals' Short term Debt amounted to $93.8 million in FY2024.
  • In the past 5 years, Alnylam Pharmaceuticals' Short term Debt registered a high of $93.8 million during FY2024, and its lowest value of $93.8 million during FY2024.
  • In the last 1 years, Alnylam Pharmaceuticals' Short term Debt had a median value of $93.8 million in 2024 and averaged $93.8 million.